According to the results of the present study, targeted therapy in combination with PD-1/PD-L1 checkpoint inhibitors significantly improved the OS and PFS for unresectable HCC compared with targeted monotherapy showed that for unresectable HCC. This evidence concerns the gene RPL17 and hepatocellular carcinoma.